Edgestream Partners L.P. Has $406,000 Position in Abbott Laboratories $ABT

Edgestream Partners L.P. lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 76.9% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 3,956 shares of the healthcare product maker’s stock after selling 13,198 shares during the quarter. Edgestream Partners L.P.’s holdings in Abbott Laboratories were worth $406,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ABT. J. Stern & Co. LLP lifted its position in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $2,938,892,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Abbott Laboratories by 217.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after purchasing an additional 3,780,402 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Abbott Laboratories by 303.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after purchasing an additional 3,330,368 shares during the last quarter. Finally, Ninety One UK Ltd acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $336,815,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on ABT shares. Benchmark decreased their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Mizuho dropped their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Evercore reduced their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Jefferies Financial Group decreased their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Stock Up 0.2%

NYSE ABT opened at $105.68 on Thursday. The business has a fifty day moving average price of $94.63 and a two-hundred day moving average price of $100.07. The stock has a market capitalization of $182.86 billion, a PE ratio of 34.20, a PEG ratio of 2.04 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the company posted $1.26 EPS. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.